MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajo.2026.06.003

Медицинская библиотека · American journal of ophthalmology · 2026

Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes.

Liberman Paulina, Yu Sophia E, Mendez Israel J, Ramos Eugenia M, Berkenstock Meghan K, Burkholder Bryn M, Thorne Jennifer E, Jabs Douglas A

СтатьяПеревод в очереди

Аннотация

PURPOSE: To determine the incidence, effect on adalimumab drug levels, and clinical consequences of antiadalimumab antibody formation, and to assess potential risk factors.

DESIGN

Retrospective clinical cohort study.

PARTICIPANTS

One hundred twenty-eight patients treated with adalimumab who underwent antiadalimumab antibody monitoring.

METHODS

Beginning October 2023, regularly scheduled antiadalimumab antibody and adalimumab level testing was begun. Using staggered entry analysis, anchored observation to treatment initiation, incidence was calculated. Time-updated models evaluated risk factors for antiadalimumab antibody formation.

MAIN OUTCOME: Incidence of antiadalimumab antibodies.

RESULTS

Antiadalimumab antibodies developed in 37 of 128 patients for a rate of 0.077 per person-year (PY) (95% confidence interval [CI] 0.055/PY, 0.104/PY). Median serum adalimumab concentrations were significantly lower in antiadalimumab antibody-positive blood samples (2.6 µg/mL; interquartile range 0.8, 7.0) than in antibody-negative samples (10.2 µg/mL; interquartile range 6.9, 15.1), P < .00001. In time-updated analyses, there was a suggestion that concomitant immunosuppression was associated with a reduced risk of antiadalimumab antibodies (odds ratio [OR] 0.64; 95% CI 0.37, 1.10; P = .10) and weekly adalimumab dosing was associated with a reduced risk (OR 0.62; 95% CI 0.42, 0.91; P = .01). Antiadalimumab antibodies were associated with active ocular inflammation (OR 3.68; 95% CI 1.99, 6.82; P < .00001).

CONCLUSIONS

Antiadalimumab antibodies occur commonly among patients treated with long-term adalimumab, with a cumulative incidence of nearly 50% by 8 years of therapy. Antibody formation was associated with lower serum adalimumab levels and active ocular inflammation.

Для цитирования: Liberman Paulina, Yu Sophia E, Mendez Israel J, Ramos Eugenia M, Berkenstock Meghan K, Burkholder Bryn M, Thorne Jennifer E, Jabs Douglas A. Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes.. American journal of ophthalmology. 2026. DOI: 10.1016/j.ajo.2026.06.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.